We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Adaptimmune Announces Interim Results from a Phase I/II Trial of Engineered T Cells

News   Dec 12, 2013

 
Adaptimmune Announces Interim Results from a Phase I/II Trial of Engineered T Cells
 
 
 

RELATED ARTICLES

It Is Possible to Extend Life Without Any Genetic Modification, Study Suggests

News

Given the relationship between telomeres and ageing - telomeres shorten throughout life, so older organisms have shorter telomeres -, scientists launched a study generating mice in which 100% of their cells had hyper-long telomeres.

READ MORE

Targeted Therapy Could Help Children With Deadly Nerve Cancer

News

Mount Sinai researchers have discovered a targeted therapy for adolescent patients with neuroblastoma, a deadly pediatric nerve cancer, who would otherwise have no treatment options.

READ MORE

Plant-based Compound Helps Overcome Gene Therapy Challenges

News

Researchers believe they have found a way to sidestep some of the current difficulties associated with gene therapy, resulting in a better method that would save money and improve treatment outcomes.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Cancer Research Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE